Physician profile
Thomas Forlenza
NPI 1619978442
$3,840.02
in general payments reported to CMS, 2019-2025
32 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $465 · 2021: $219 · 2022: $577 · 2023: $727 · 2024: $160 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $622.73 | 2019-2025 | Opdivo, Augtyro |
| Daiichi Sankyo INC. | $422.73 | 2021-2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $384.53 | 2019-2024 | |
| Janssen Biotech, INC. | $307.14 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $274.73 | 2020-2023 | Kyprolis, Lumakras |
| Pfizer INC. | $255.52 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $214.94 | 2019-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $161.46 | 2022-2025 | Zejula, Jemperli |
| Syndax Pharmaceuticals, INC. | $148.21 | 2025 | Revuforj |
| Genentech USA, INC. | $145.36 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $118.55 | 2021-2022 | |
| Gilead Sciences, INC. | $98.74 | 2019-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $74.67 | 2019-2025 | Gavreto, Rezlidhia, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $68.50 | 2019-2020 | |
| Astellas Pharma US INC | $59.86 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.00 | 2019 | |
| Foundation Medicine, INC. | $49.12 | 2023 | |
| Abbvie INC. | $48.75 | 2019-2020 | |
| Exelixis INC. | $43.99 | 2019-2024 | Cabometyx |
| Incyte Corporation | $40.88 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.89 | 2019-2023 | |
| Servier Pharmaceuticals LLC | $24.68 | 2025 | |
| Immunomedics, INC. | $24.48 | 2020 | |
| Aadi Bioscience, INC. | $23.60 | 2024 | Fyarro |
| Lilly USA, LLC | $23.40 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.14 | 2020 | |
| Sumitomo Pharma America, INC. | $19.11 | 2023 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $17.65 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.67 | 2020 | |
| Celgene Corporation | $16.50 | 2019 | |
| Kyowa Kirin, INC. | $14.72 | 2019 | |
| Eisai INC. | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Forlenza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.